SEARCH

SEARCH BY CITATION

References

  • 1
    Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 (Suppl. 1):S3.
  • 2
    Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11:180210.
  • 3
    Gaujoux-Viala C, Mouterde G, Baillet A et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 2012; 79:149155.
  • 4
    Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62:2232.
  • 5
    Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008; 26:831846.
  • 6
    Dupond JL. Fatigue in patients with rheumatic diseases. Joint Bone Spine 2011; 78:156160.
  • 7
    Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009; 11 (Suppl. 1):S1.
  • 8
    Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:14601468.
  • 9
    Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12:217.
  • 10
    Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011; 63:867870.
  • 11
    Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68:17391745.
  • 12
    Semerano L, Assier E, Delavallee L, Boissier MC. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011; 11:545550.
  • 13
    Biton J, Semerano L, Delavallee L et al. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 2011; 186:38993910.
  • 14
    Le Buanec H, Delavallee L, Bessis N et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006; 103:1944219447.
  • 15
    Delavallee L, Le Buanec H, Bessis N et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008; 67:13321338.
  • 16
    Delavallee L, Semerano L, Assier E et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009; 11:R195.
  • 17
    Hayward MD, Jones BK, Saparov A et al. An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol 2007; 7:13.
  • 18
    Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:40254031.
  • 19
    Clavel G, Marchiol-Fournigault C, Renault G, Boissier MC, Fradelizi D, Bessis N. Ultrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Ann Rheum Dis 2008; 67:17651772.
  • 20
    Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300:230235.
  • 21
    European Medicines Agency. European Public Assessment Reports (EPARs) infliximab. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000240/WC500050885.pdf (accessed October 2012).
  • 22
    European Medicines Agency. European Public Assessment Reports (EPARs) adalimumab. 2004. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000481/WC500050867.pdf (accessed October 2012).